Russian signed agreement to produce Sputnik V vaccine in India - RDIF
The Russian Direct Investment Fund (RDIF) has signed an agreement with Indian companies on production of 300 million doses of the Sputnik V coronavirus vaccine per year, RDIF head Kirill Dmitriev said in an interview with Indian television channel NDTV.
"We have already reached an agreement with Indian companies to produce more than 300 million doses of Russian vaccine per year," he said.
Dmitriev also noted that the results of the study of the Sputnik V vaccine will be published this week. "Our scientists have proven that even those people who have previously had adenovirus have a 100% effect from the vaccine and a 100% increase in the level of antibodies in the blood," he added.
Earlier, Alexander Gintsburg, head of the the Gamaleya National Research Center for Epidemiology and Microbiology said that it is planned to attract about 40,000 volunteers to the third stage of the study of the Russian coronavirus vaccine.
Registered on August 11, Russia’s Sputnik V became the first vaccine against the coronavirus worldwide that obtained state registration. It was developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry. The vaccine passed clinical testing in June-July. Earlier, Dmitriev said that the Russian Federation has already received applications from 20 countries for the supply of 1 billion doses of vaccine.